论文部分内容阅读
目的:研究甘精胰岛素联合格列美脲、吡格列酮两种药物对糖基血红蛋白(HbAlc)>9%的2型糖尿病(T2DM)患者治疗有效性。方法:选取诊治的HbAlc>9%的新诊断2型糖尿病患者80例,随机分为格列美脲组与吡格列酮组各40例,以非药物治疗、甘精胰岛素治疗为基础,格列美脲组使用格列美脲治疗、吡格列酮组使用吡格列酮治疗,观察两组治疗疗效。结果:空腹血糖(FBG)、餐后2 h血糖(2 hPG)、HbAlc治疗前、后两组组间比较,差异均无统计学意义(P>0.05),两组组内比较,差异具有统计学意义(P<0.05);格列美脲组甘精胰岛素剂量、血糖控制达标时间、低血糖发生率少于吡格列酮组,两组数据比较差异具有统计学意义(P<0.05)。结论:甘精胰岛素联合格列美脲和吡格列酮对HbAlc>9%的T2DM均可起到良好治疗效果,但联合格列美脲时血糖控制达标时间更短、低血糖发生率较低。
Objective: To study the efficacy of glargine combined with glimepiride and pioglitazone in the treatment of type 2 diabetes mellitus (T2DM) patients with glycohemoglobin (HbAlc)> 9%. Methods: Eighty newly diagnosed type 2 diabetic patients with HbA1c> 9% were randomly divided into 40 cases in the glimepiride group and the pioglitazone group. On the basis of non-drug treatment and insulin glargine treatment, Group treated with glimepiride, pioglitazone group treated with pioglitazone, observed two groups of curative effect. Results: There was no significant difference between fasting blood glucose (FBG), postprandial 2h blood glucose (2hPG) and HbAlc before and after treatment (P> 0.05), and there were statistically significant differences between the two groups (P <0.05). The insulin glargine dosage, glycemic control time, and the incidence of hypoglycemia in glimepiride group were less than those in pioglitazone group. The difference between the two groups was statistically significant (P <0.05). CONCLUSIONS: Glargine, glimepiride and pioglitazone are effective in treating T2DM with HbA1c> 9%. However, the glycemic control with glimepiride is shorter and the incidence of hypoglycemia is lower.